Mercy Research

Closed portfolio with a later-stage archive tilt

According to ClinicalTrials.gov-derived indexes, Mercy Research sits in the top decile of US sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count).

14 total trials none currently recruiting 12 completed later-stage tilt top decile by trial count

Mercy Research: 14 sponsored US clinical trials, none currently recruiting.

Mercy Research sponsors 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 12 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Benign Spinal Tumors, with 1 trials.

Top-decile sponsor footprint

Mercy Research ranks in the top decile of sponsors by registered trial count (#987 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 71/100

12 of 13 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (92.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

14 total, page 1 of 1

ACTIVE NOT RECRUITING NA

Subclinical Lymphedema Treatment Study

NCT03292198
TERMINATED NA

Application of the ICE-T Postoperative Multimodal Pain Regimen to Laparoscopic Hysterectomy

NCT04137770
COMPLETED NA

Ultravision™ System to Facilitate Low Impact Laparoscopic Surgery for Endometriosis

NCT03956082
COMPLETED NA

Ultravision Visual Clearing System in Laparoscopic Hysterectomy and Myomectomy

NCT03634306
COMPLETED NA

Patient Anxiety Associated With Lymphedema Surveillance Method

NCT02033759
COMPLETED NA

A Comparison of Meperidine for Post-Cesarean Analgesia: Bolus Versus Infusion and Bolus

NCT01741259
COMPLETED NA

Stereotactic Body Radiotherapy for Prostate Cancer

NCT01352598
COMPLETED

The Effect of Three Different Fluids(Albumin 5%, Normal Saline, Hydroxyethyl Starch 130 kD) on Microcirculation in Severe Sepsis/Septic Shock Patients

NCT01319630
COMPLETED NA

Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®

NCT01448447
COMPLETED NA

Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function

NCT01056718
COMPLETED NA

Stereotactic Body Radiotherapy for Spine Tumors

NCT01347307
COMPLETED NA

Stereotactic Body Radiotherapy for Unresectable Pancreatic Cancer

NCT01346410
COMPLETED NA

Stereotactic Body Radiotherapy for Liver Tumors

NCT01347333
COMPLETED Phase 4

Stereotactic Body Radiotherapy for Head and Neck Tumors

NCT01344356

Phase Distribution

PhaseTrial count
Phase 4 1

Therapeutic Areas

Benign Spinal Tumors 1
Vertebral Metastases 1
Breast Cancer-related Subclinical Lymphedema 1
Hysterectomy 1
Paragangliomas 1
Myomectomy 1
Neurofibroma 1
Spinal Metastases 1
Arteriovenous Malformations 1
Schwannoma 1

How the Mercy Research archive is shaped

14 indexed studies, none listed as recruiting (0% open); 12 completed (86%).

Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).

Top condition: Benign Spinal Tumors (1 trial), 9 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Mercy Research: archived-pipeline peers nationwide

Peers matched on 14 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Mercy Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%0.0%0.0%0.1% Total trials Recruiting share Mercy Research3-C Institute for Social DevelopmentAbbott Medical OpticsAbbott RDx CardiometabolicAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA10xBio22nd Century Group23andMe3 Waves Wellness
Mercy Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Mercy Research sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 14 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Mercy Research page

14 registered trials is a research-attention snapshot, not an endorsement of Mercy Research or any single study.

  • None of Mercy Research's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Benign Spinal Tumors is the condition Mercy Research studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Benign Spinal Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Mercy Research pipeline card: 14 registered trials from official public datasets.Report a data error.